title: [Research on therapeutic effect of yangganjiejiu prescription on alcoholic fatty liver and its mechanism].
abstract: OBJECTIVE
  To research pharmacodynamic effect of Yangganjiejiu prescription on alcoholic fatty liver and its mechanism.
  
  
  METHODS
  The alcoholic fatty liver models of rats was set up by feeding high fat diet and alcohol. Sixty male SD rats were randomly divided into 6 groups: normal group, model group, low-dose Yangganjiejiu prescription group (0.7 g/kg), medial-dose group (1.4 g/kg), high-dose group (2.8 g/kg) and positive control drug Dongbao Gantai group, 10 rats were in each group.
  
  
  RESULTS
  Yangganjiejiu prescription (1.4 and 2.8 g/kg) could significantly reduce alcoholic fatty liver rats' serum and liver tissues of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol( LDL-C) levels (compared with the model group, P < 0.05) and lower serum free fatty acids (FFA) content (compared with the model group, P < 0.05), and to some extent increase the serum and liver tissues of high-density lipoprotein (HDL-C) levels (but compared with the model group, there was no statistical significance, P > 0.05); It could improve liver function, lower serum AST, ALP and GGT content (compared with the model group, P < 0.05 or P < 0.01), significantly decrease serum and liver tissue MDA (P < 0.01), increase SOD in serum and liver tissue (P < 0.01), alleviate alcoholic fatty on the liver secondary liver pathology, and reduce fatty liver.
  
  
  CONCLUSIONS
  Yangganjiejiu prescription has preventive and therapeutic effect on alcoholic fatty liver. Its mechanism is closely related to resistance to oxidative damage, reducing blood lipid, protecting liver and lowering transaminase.
authors.forename: Jian-Wen
authors.initials: JW
authors.lastname: Chen
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Zhao-Yun
authors.initials: ZY
authors.lastname: Xue
authors.forename: Bao
authors.initials: B
authors.lastname: Chen
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Shao-Rui
authors.initials: SR
authors.lastname: Chen
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D059305:Diet, High-Fat / Q000009:adverse effects; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005235:Fatty Liver, Alcoholic / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000097:blood
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D008055:Lipids; D008315:Malondialdehyde; D013482:Superoxide Dismutase; D000410:Alanine Transaminase